Shifting of Corporate office w.e.f. May 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Microcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Oxygenta Pharmaceutical has shifted its corporate office within Hyderabad from Gachibowli (Lumbini Avenue) to Kukatpally (IDA Gandhi Nagar), effective May 30, 2025. Alongside, the Board approved audited results for FY25 showing revenue from operations surging to Rs 10,929.86 lakhs, nearly 2.8x the Rs 3,964.21 lakhs reported in FY24, driven by a strong Q4 where revenue jumped to Rs 4,946.66 lakhs from Rs 1,055.24 lakhs a year ago. However, the net loss widened sharply to Rs 1,029.83 lakhs in FY25 from Rs 347.93 lakhs in FY24, and Q4 posted a loss of Rs 215.29 lakhs. The company carries a negative net worth of Rs 2,564.05 lakhs (accumulated losses of Rs 6,262.40 lakhs against equity capital of Rs 3,698.35 lakhs) and reported negative operating cash flow of Rs 1,124.91 lakhs for the year. Exceptional items of Rs 27 lakhs relate to provident fund damages. The statutory auditor (M/s AM Reddy & DR Reddy) issued an unmodified (clean) opinion on the results.
While top-line growth is very strong, deepening losses, negative net worth, and persistent cash burn raise serious concerns about financial sustainability, which shareholders should monitor closely despite the clean audit opinion and operational expansion implied by the revenue jump.